Tamoxifen induction of aryl sulfotransferase and hydroxysteroid sulfotransferase in male and female rat liver and intestine

Drug Metabolism and Disposition

Volumn 31, Issue 5, 2003, Pages 637-644

  Maiti, Smarajit ^a   Chen, Guangping ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ARYL SULFOTRANSFERASE; CORN OIL; DRUG METABOLIZING ENZYME; HYDROXYSTEROID SULFOTRANSFERASE; HYDROXYTAMOXIFEN; MESSENGER RNA; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CARCINOGENICITY; DRUG DETOXIFICATION; DRUG METABOLISM; ENZYME ASSAY; ENZYME INDUCTION; FEMALE; INTESTINE EPITHELIUM CELL; LIVER CYTOSOL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SPECIES DIFFERENCE; TISSUE SPECIFICITY; WESTERN BLOTTING;

ANIMALS; ARYLSULFOTRANSFERASE; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INDUCTION; ESTROGEN ANTAGONISTS; FEMALE; INTESTINES; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFOTRANSFERASES; TAMOXIFEN;

ANIMALIA; ZEA MAYS;

EID: 0037403445     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.5.637     Document Type: Conference Paper

References (54)

1. Aldred S and Waring RH (1999) Localisation of dehydroepiandrosterone sulphotransferase in adult rat brain. Brain Res Bull 48:291-296.
2. Baranczyk-Kuzma A, Garren JA, Hidalgo IJ, and Borchardt RT (1991) Substrate specificity and some properties of phenol sulfotransferase from human intestinal Caco-2 cells. Life Sci 49:1197-1206.
3. Beland FA, McDaniel LP, and Marques MM (1999) Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 20:471-477.
4. Bjorge S, Hamelehle KL, Homan R, Rose SE, Turluck DA, and Wright DS (1991) Evidence for glucuronide conjugation of p-nitrophenol in the Caco-2 cell model. Pharm Res (NY) 8:1441-1443.
5. Boocock DJ, Maggs JL, Brown K, White IN, and Park BK (2000) Major inter species differences in the rates of O-sulphonation and O-glucuronylation of α-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis 21:1851-1858.
6. Campbell-Thompson M, Lynch IJ, and Bhardwaj B (2001) Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res 61:632-640.
7. Cappiello M, Franchi M, Giuliani L, and Pacifici GM (1989) Distribution of 2-naphthol sulphotransferase and its endogenous substrate adenosine 3′-phosphate 5′ phosphosulphate in human tissues. Eur J Clin Pharmacol 37:317-320.
8. Carthew P, Martin EA, White IN, De Matteis F, Edwards RE, Dorman BM, Heydon RT, and Smith LL (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res 55:544-547.
9. Chen G, Baron J, and Duffel MW (1995) Enzyme- and sex-specific differences in the intralobular localizations and distributions of aryl sulfotransferase IV (tyrosine-ester sulfotransferase) and alcohol (hydroxysteroid) sulfotransferase a in rat liver. Drug Metab Dispas 23:1346-1353.
10. Chen G, Battaglia E, Senay C, Falany CN, and Radominska-Pandya A (1999) Photoaffinity labeling probe for the substrate binding site of human phenol sulfotransferase (SULTIAI): 7-azido-4-methylcoumarin. Protein Sci 10:2151-2157.
11. Chen G, Rabjohn PA, York JL, Wooldridge C, Zhang D, Falany CN, and Radominska-Pandya A (2000) Carboxyl residues in the active site of human phenol sulfotransferase (SULTIAI). Biochemistry 39:16000-16007.
12. Chen G, Yin S, Maiti S, and Shao X (2002) Four hydroxy tamoxifen sulfation metabolisms. J Biochem Mol Toxicol 16:279-285.
13. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, and Soo KC (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36:1221-1226.
14. Crewe HK, Ellis SW, Lennard MS, and Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171-178.
15. Davis W, Hewer A, Rajkowski KM, Meinl W, Glatt H, and Phillips DH (2000) Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: role of sulfotransferase induction. Cancer Res 60:2887-2891.
16. Dehal SS and Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402-3406.
17. Duffel MW, Binder TP, Hosie L, Baden HA, Sanders JA, Knapp SA, and Baron J (1991) Purification, immunochemical characterization and immunohistochemical localization of rat hepatic aryl sulfotransferase IV. Mol Pharmacol 40:36-44.
18. Falany CN and Wilborn TW (1994) Biochemistry of cytosolic sulfotransferases involved in bioactivation. Adv Pharmacol 27:301-329.
19. Firozi PF, Vulimiri SV, Rajaniemi H, Hemminki K, Dragan, Pitot HC, DiGiovanni J, Zhu YH, and Li D (2000) Characterization of the major DNA adducts in the liver of rats chronically exposed to tamoxifen for 18 months. Chem Biol Interact 126:33-43.
20. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J., et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
21. Gee JM and Johnson IT (2001) Polyphenolic compounds: interactions with the gut and implications for human health. Curr Med Chem 11:1245-1255.
22. Glatt H, Bartsch I, Christoph S, Coughtrie MW, Falany CN, Hagen M, Landsiedel R, Pabel U, Phillips DH, Seidel A, et al. (1998a) Sulfotransferase-mediated activation of mutagens studied using heterologous expression systems. Chem Biol Interact 109:195-219.
23. Glatt H, Davis W, Meinl W, Hermersdorfer H, Venitt S, and Phillips DH (1998b) Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 19:1709-1713.
24. Greaves P, Goonetilleke R, Nunn G, Topham J, and Orton T (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924.
25. Harris RM, Waring RH, Kirk CJ, and Hughes PJ (2000) Sulfation of "estrogenic" alkylphenols and 17,β-estradiol by human platelet phenol sulfotransferases. J Biol Chem 275:159-166.
26. Heel RC, Brogden RN, Speight TM, and Avery GS (1978) Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16:1-24.
27. Hellriegel ET, Matwyshyn GA, Fei P, Dragnev KH, Nims RW, Lubet RA, and Kong AN (1996) Regulation of gene expression of various phase I and phase II drug-metabolizing enzymes by tamoxifen in rat liver. Biochem Pharmacol 52:1561-1568.
28. Hemminki K, Rajaniemi H, Lindahl B, and Moberger B (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56:4374-4377.
29. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, and Berthou F (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911-1919.
30. Jarman M, Poon GK, Rowlands MG, Grimshaw RM, Horton MN, Potter GA, and McCague R (1995) The deuterium isotope effect for the α-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl] tamoxifen. Carcinogenesis 16:683-688.
31. Jordan VC (1988) The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole, Breast Cancer Res Treat 11:197-209.
32. Kasahara T, Hashiba M, Harada T, and Degawa M (2002) Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats. Carcinogenesis 23:491-498.
33. Lampen A, Bader A, Bestmann T, Winkler M, Witte L, and Borlak JT (1998) Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. Xenobiotica 28:429-441.
34. Mani C, Hodgson E, and Kupfer D (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. vc Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab Dispos 21:657-661.
35. Martin EA, Heydon RT, Brown K, Brown JE, Lim CK, White IN, and Smith LL (1998) Evaluation of tamoxifen and α-hydroxytamoxifen 32P-post-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis 19:1061-1069.
36. Matsui M and Homma H (1994) Biochemistry and molecular biology of drug metabolizing sulfotransferase. Int J Biochem 26:1237-1247.
37. Moorthy B, Sriram P, Pathak DN, Bodell WJ, and Randerath K (1996) Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res 56:53-57.
38. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, and Watabe T (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830.
39. Nuwaysir EF, Daggett DA, Jordan VC, and Pitot HC (1996) Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. Cancer Res 56:3704-3710.
40. Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, and Muraro GB (1988) Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 18:849-856.
41. Parker CR Jr (1999) Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging. Steroids 64:640-647.
42. Pasqualini JR and Chetrite GS (1999) Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J Steroid Biochem Mol Biol 69:287-292.
43. Peters WH and Roelofs HM (1992) Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases. Cancer Res 52:1886-1890.
44. Poon GK, Walter B, Lonning PE, Horton MN, and McCague R (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate and patients on long-term therapy for breast cancer. Drug Metab Dispos 23:377-382.
45. Rajkowski KM, Robel P, and Baulieu EE (1997) Hydroxysteroid sulfotransferase activity in the rat brain and liver as a function of age and sex. Steroids 62:427-436.
46. Rosenberg DW and Leff T (1993) Regulation of cytochrome P450 in cultured human colonic cells. Arch Biochem Biophys 300:186-192.
47. Runge-Morris M, Rose K, Falany CN, and Kocarek TA (1998) Differential regulation of individual sulfotransferase isoforms by phenobarbital in male rat liver. Drug Metab Dispos 26:795-801.
48. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, and Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651.
49. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, and Watkins PB (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrixcoated permeable supports in the presence of Iα. 25-dihydroxyvitamin D3. Mol Pharmacol 51:741-754.
50. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, et al. (2000) Phenol sulfotransferases: hormonal regulation, polymorphism and age of onset of breast cancer. Cancer Res 60:6859-6863.
51. Shibutani S, Dasaradhi L, Terashima I, Banoglu E, and Duffel MW (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase. resulting in tamoxifen DNA adducts. Cancer Res 58:647-653.
52. Sundaram RS, Szumlanski C, Otterness D, van Loon JA, and Weinshilboum RM (1989) Human intestinal phenol sulfotransferase: assay conditions, activity levels and partial purification of the thermolabile form. Drug Metab Dispos 17:255-264.
53. Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR and PPAR. Arch Biochem Biophys 369:11-23.
54. Witte D, Chirala M, Younes A, Li Y, and Younes M (2001) Estrogen receptor β is expressed in human colorectal adenocarcinoma. Hum Pathol 32:940-944.